Services

Launching a first-in-class therapy for an ultra-rare condition: this was a new disease area for our client, and there was no licensed treatment available. Disease awareness was minimal, and so diagnosis rates were low. Our brief was to create an awareness among stakeholders for the need for treatment and develop the launch materials.

A mid-sized biotech client sought to develop and validate a payer value proposition for a first-in-class drug indicated for a rare form of dysmorphic short stature.

The condition was considered ‘low impact’ by many key stakeholders, leading to a reluctance to treat. Our challenge was to give a voice to those affected and overcome entrenched scepticism.

A major multinational pharma client wanted to prepare for ongoing and future payer engagements for three high-priority legacy products across multiple markets in Europe and Latin America.